Pulmonary hypertension and right ventricular failure in left ventricular systolic dysfunction

Current Opinion in Cardiology

Volumn 27, Issue 3, 2012, Pages 262-272

  Di Salvo, Thomas G ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

heart failure; left ventricular dysfunction; pulmonary hypertension; right ventricular failure

Indexed keywords

BOSENTAN; CYCLIC GMP; ENDOTHELIN RECEPTOR ANTAGONIST; MILRINONE; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN; SILDENAFIL;

CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL FEATURE; DIASTOLIC HEART FAILURE; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; EXERCISE; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMIC MONITORING; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LUNG PRESSURE; LUNG VASCULAR RESISTANCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE;

EXERCISE TOLERANCE; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; QUALITY OF LIFE; RISK FACTORS; SYSTOLE; VASCULAR RESISTANCE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84859897554     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283522098     Document Type: Review

References (92)

1. Guazzi M, Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol 2010; 7:648-659.
2. Guglin M, Khan H. Pulmonary hypertension in heart failure. J Card Fail 2010; 16:461-474.
3. Haddad F, Kudelko K, Mercier O, et al. Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. Prog Cardiovasc Dis 2011; 54:154-167.
4. Shin J, Semigran M. Heart failure and pulmonary hypertension. Heart Fail Clin 2010; 6:215-222.
5. Simonneau G, Robbins I, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S43-S54.
6. Hoeper M, Barbera A, Channick R, et al. Diagnosis, assessment and treatment of nonpulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009; 54:S85-S96.
7. Chatterjee N, Lewis G. What is the prognostic significance of pulmonary hypertension in heart failure? Circ Heart Fail 2011 4 541-545.
8. West J, Mathieu-Costello O. Vulnerability of pulmonary capillaries in heart disease. Circulation 1995; 92:622-631.
9. Huang W, Kingsbury M, Turner M, et al. Capillary filtration is reduced in lungs adapted to chronic heart failure: morphological and hemodynamic correlates. Cardiovasc Res 2001; 49:207-217.
10. Kingsbury M, Huang W, Donnelly L, et al. Structural remodelling of lungs in chronic heart failure. Basic Res Cardiol 2003; 98:295-303. (Pubitemid 37107656)
11. Negrini D, Passi A, de Luca G, Miserocchi G. Pulmonary interstitial pressure and proteoglycans during development of pulmonary edema. Am J Physiol 1996; 270:H2000-H2007.
12. Palestini P, Calvi C, Conforti E, et al. Composition, biochemical properties, and morphometry of plasma membranes in pulmonary interstitial edema. Am J Physiol Lung Cell Mol Physiol 2002; 282:L1382-L1390. (Pubitemid 34654596)
13. Guazzi M. Alveolar gas diffusion abnormalities in heart failure. J Card Fail 2008; 14:695-702.
14. Pietra G, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43:25S-32S. (Pubitemid 38759714)
15. Delgado J, Conde E, Sanchez V, et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2004; 7:1011-1016.
16. Rich S, Rabinovitch M. Diagnosis and treatment of secondary (noncategory) pulmonary hypertension. Circulation 2008; 118:2190-2199.
17. Champion H, Michelakis E, Hassoun P. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 2009; 120:992-1007.
18. Pagnamenta A, Dewachter C, McEntee K, et al. Early right ventriculo-arterial uncoupling in borderline pulmonary hypertension on experimental heart failure. J Appl Physiol 2010; 109:1080-1085.
19. Hunter K, Lee P, Lanning C, et al. Pulmonary vascular impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension. Am Heart J 2008; 155:166-174. (Pubitemid 350234769)
20. Miller W, Mahoney D, Michelena H, et al. Contribution of ventricular diastolic dysfunction to pulmonary hypertension complicating chronic systolic heart failure. JACC Cardiovasc Imaging 2011; 4:946-954.
21. Enriquez-Sarano M, Rossi A, Seward J, et al. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol 1997; 29:153-159. (Pubitemid 27028733)
22. Lam C, Borlaug B, Kane G, et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 2009; 119:2663-2670.
23. Haddad F, Doyle R, Murphy D, Hunt S. Right ventricular function in cardiovascular disease part II: pathophysiology, clinical importance and management of right ventricular failure. Circulation 2008; 117:1717-1731. (Pubitemid 351482595)
24. Voelkel N, Quaife R, Leinwand L, et al. Right ventricular function and failure: report of a National Heart, Lung, Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006; 114:1883-1891. (Pubitemid 44673364)
25. Anderson R, Smerup M, Sanchez-Quintana D, et al. The three-dimensional arrangement of the myocytes in the ventricular walls. Clin Anat 2009; 22:64-76
26. Greyson C. Pathophysiology of right ventricular failure. Crit Care Med 2008; 36:S57-S65.
27. Bogaard H, Abe K, Noordegraaf A, Voelkel N. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009; 135:794-804.
28. Bogaard H, Natarajan R, Henderson S, et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009; 120:1951-1960.
29. Haddad F, Ahsley E, Michelakis E. New insights for the diagnosis and management of right ventricular failure, from molecular imaging to targeted right ventricular therapy. Curr Opin Cardiol 2010; 25:131-140.
30. Banerjee D, Haddad F, Zamanian R, Nagendran J. Right ventricular failure: a novel era of targeted therapy. Curr Heart Fail Rep 2010; 7:202-211.
31. Urashima T, Zhao M, Wagner R, et al. Molecular and physiological characterization of RV remodeling in a murine model of pulmonary stenosis. Am J Physiol Heart Circ Physiol 2008; 295:H1351-H1368.
32. Archer S, Weir K, Wilkins M. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010; 121:2045-2066.
33. Abramson S, Burke J, Kelly J, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 1992; 116:888-895. (Pubitemid 23034779)
34. Khush K, Tasissa G, Butler J, et al. Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catherization Effectiveness (ESCAPE) database. Am Heart J 2009; 157:1026-1034.
35. Kjaergaard J, Akkan D, Iversen K, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol 2007; 99:1146-1150. (Pubitemid 46578202)
36. Cappola T, Felker G, Kao W, et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002; 105:1663-1668. (Pubitemid 34298609)
37. Aronson D, Amon E, Dragu R, Burger A. Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure. Circ Heart Fail 2011; 4:644-650.
38. Stevenson L, Tillisch J, Hamilton M, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction-20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1990; 66:1348-1354.
39. Butler J, Chomsky D, Wilson J. Pulmonary hypertension and exercise in exercise intolerance in patients with heart failure. J Am Coll Cardiol 1999; 34:1802-1806.
40. Franciosa J, Baker B, Seth L. Pulmonary versus systemic hemodynamics on determining exercise capacity of patients with chronic left ventricular heart failure. Am Heart J 1985; 110:807-813. (Pubitemid 16027010)
41. Lewis G, Shah R, Pappagianopolas P, et al. Determinants of ventilatory efficiency in heart failure: the role of right ventricular perfomance and pulmonary vascular tone. Circ Heart Fail 2008; 1:227-233.
42. Lewis G, Murphy R, Shah R, et al. Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes. Circ Heart Fail 2011; 4:276-285.
43. Butler J, Stankewicz M, Wu J, et al. Pretransplant reversible pulmonary hypertension predicts higher risk of mortality after cardiac transplantation. J Heart Lung Transplant 2003; 24:170-177.
44. Bhatia S, Kirshenbaum J, Shemin R, et al. Time course of resolution of pulmonary hypertension and right ventricular remodeling after orthotopic cardiac transplantation. Circulation 1987; 76:819-826. (Pubitemid 17151340)
45. Chau E, Bailey K, Mahoney D, et al. Predictors of reversibility of pulmonary hypertension in cardiac transplant recipients in the first postoperative year. Circulation 1996; 94 (9 Suppl):II267-II272. (Pubitemid 26363404)
46. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37:183-188. (Pubitemid 32051736)
47. Di Salvo T, Mathier M, Semigran M, Dec G. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 1995; 25:1143-1153.
48. Gavazzi A, Ghio S, Scelsi L, et al. Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension. Am Heart J 2003; 145:310-316. (Pubitemid 36207953)
49. Meyer P, Filippatos GS, Ahmed M, et al. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation 2010; 121:252-258.
50. Di Salvo T, Acker M, Dec G, Byrne J. Mitral valve surgery in advanced heart failure. J Am Coll Cardiol 2010; 55:271-282.
51. Gehlbach B, Geppert E. The pulmonary manifestations of left heart failure. Chest 2004; 125:669-682. (Pubitemid 38223649)
52. Abraham W, Adamson P, Bourge R, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011; 337:658-666.
53. Krum H. Telemonitoring of fluid status in heart failure: CHAMPION. Lancet 2011; 377:616-618.
54. Jessup M, Abraham W, Casey D, et al. 2009 Focused Update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2009; 119:1977-2016.
55. Lindenfeld J, Albert N, Boehmer J, et al. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010; 16:475-540.
56. Barst R, Gibbs S, Ghofrani H, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S78-S84.
57. Badesch D, Abman S, Simmoneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131:1917-1928. (Pubitemid 46981654)
58. Agarwal R, Gomberg-Maitland M. Current therapeutics and practical management strategies for pulmonary arterial hypertension. Am Heart J 2011; 162:201-213.
59. Califf R, Adams K, McKenna W, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134:44-54. (Pubitemid 27329022)
60. Packer M, McNurray J, Massie B, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with chronic heart failure: results of a pilot study. J Card Fail 2005; 11:12-20. (Pubitemid 40215308)
61. Kaira P, Moon J, Coats A. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for nonselective endothelin antagonism in heart failure? Int J Cardiol 2002 85 195-197. (Pubitemid 35245980)
62. Lahm T, McCaslin C, Wozniak T, et al. Medical and surgical treatment of acute right ventricular failure. J Am Coll Cardiol 2010; 56:1435-1446.
63. Hare J, Shernan S, Body S, et al. Influence of inhaled nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance. Circulation 1997; 95:2250-2253. (Pubitemid 27191001)
64. Argenziano M, Choudhri A, Moazami N, et al. Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension. Ann Thorac Surg 1998; 65:340-345. (Pubitemid 28083325)
65. Guazzi M. Clinical use of Phosphodiesterase-5 inhibitors in chronic heart failure. Circ Heart Fail 2008; 1:272-280.
66. Kass D. Res-erection of Viagra as a heart drug. Circ Heart Fail 2011; 4: 2-4.
67. Galie N, Ghofrani H, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New Engl J Med 2005; 353:2148-2157. (Pubitemid 41653106)
68. Nagendran J, Archer S, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007; 116:238-248. (Pubitemid 47196559)
69. Archer S, Michelakis E. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 2009; 361:1864-1871.
70. Guazzi M, Tumminello G, Di Marco F, et al. The effects of phosphodiesterase- 5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004; 44:2339-2348. (Pubitemid 39647608)
71. Lewis G, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007; 115:59-66. (Pubitemid 46058612)
72. Melenovsky V, Al-Hiti H, Kazdova L, et al. Transpulmonary b-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension. J Am Coll Cardiol 2009; 54:595-600.
73. Alaeddini J, Uber P, Park M, et al. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 2004; 94:1475-1477. (Pubitemid 39556232)
74. Lepore J, Maroo A, Bigatello L, et al. Hemodynamic effects of sildenafil on patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005; 127:1647-1653. (Pubitemid 46218790)
75. Lewis G, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116:1555-1562. (Pubitemid 47511419)
76. Guazzi M,Samaja M, Arena R, et al. Long-termuse of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50:2136-2144. (Pubitemid 350117342)
77. Behling A, Rohde L, Colombo F, et al. Effects of 50-phosphodiesterase fourweek long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 2008; 14:189-197. (Pubitemid 351444866)
78. Guazzi M, Vicenzi M, Arena R, Guazzi M. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable heart failure: results of a 1-year, prospective, randomized, placebo-controlled trial. Circ Heart Fail 2011; 4:8-17.
79. Tedford R, Hemmes A, Russell S, et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail 2008; 1:213-219.
80. Guazzi M, Vicenzi M, Arena R, Guazzi M. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011; 124:164-174.
81. Pokreisz P, Vandenwijngaert S, Vito B, et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 2009; 119:408-416.
82. Zhang M, Takimoto E, Hsu S, et al. Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type-5. J Am Coll Cardiol 2010; 56:2021-2030.
83. Stehlik J, Movsesian M. Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure. J Card Fail 2009; 15:31-34.
84. Givertz M, Hare J, Loh E, et al. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol 1996; 28:1775-1780. (Pubitemid 26426234)
85. Haraldsson A, Kieler-Jensen N, Ricksten S. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001; 93:1439-1445. (Pubitemid 33111666)
86. Bleeker G, Schalij M, Nihoyannopoulos P, et al. Left ventricular dyssnchrony predicts right ventricular remodeling after cardiac resychronization therapy. J Am Coll Cardiol 2005; 46:2264-2269. (Pubitemid 41785495)
87. Verhaert D, Grimm R, Puntawangkoon C, et al. Long-term reverse remodeling withcardiacresynchronizationtherapy.JAmCollCardiol2010;55:1788-1795.
88. Rajagopalan N, Suffoletto M, Tanabe M, et al. Right ventricular function following cardiac resynchronization therapy. Am J Cardiol 2007; 100:1434-1436. (Pubitemid 47576026)
89. Shalaby A, Voigt A, El-Saed A, Saba S. Usefulness of pulmonary artery pressure by echocardiography to predict outcome in patients receiving cardiac resynchronization therapy. Am J Cardiol 2008; 101:238-241.
90. Healey J, Davies R, Tang A. Improvement of apparently fixed pulmonary hypertension with cardiac resynchronization therapy. J Heart Lung Transplant 2004; 23:650-652. (Pubitemid 38595757)
91. Etz C, Welp H, Tjan T, et al. Medically refractory pulmonary hypertension: treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg 2007; 83:1697-1706.
92. Zimpfer D, Zrunek P, Roethy W, et al. Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg 2007; 133:689-695.